[EuroTimes] Drug helps relieve DRY EYE2019-05-10
BRM421 interrupts the dry eye vicious cycle and has the potential to control inflammation induced by DAMP, reducing subsequent tissue oedema and damage[*Read more ...]
環球生技2016 Jan-Feb 刊登有關全福生技與財團法人生物技術開發中心於2015年12月16日在中研院舉辦的Dengue Disease: from Epidemiology to Treatment 相關報導。[*Read more ...]
感謝大家參與12/15於中研院人文社會館舉辦的“Dengue Diseases: from Epidemiology to Treatment”研討會
Dengue Diseases: from Epidemiology to Treatment2015-11-20
Dengue Diseases: from Epidemiology to Treatment
BRIM appearing on BioCentury: How BRIM is bridging a translational science gap in Taiwan2015-11-16
Bridge to POC
BRIM Biotechnology Inc. has assembled a team of translational science veterans to fill what it sees as a gap in Taiwanese drug development capabilities. The company plans to bring in preclinical projects with global commercialization potential and develop them through Phase Ia or IIb proof of concept, then sell them or find a partner to complete development outside of Taiwan or Asia.
BRIM seeks global rights to programs from academic groups, multinationals and biotechs. The company has four preclinical programs, including two cancer biologics and one dengue fever collaboration with a Johnson & Johnson unit.